<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961998</url>
  </required_header>
  <id_info>
    <org_study_id>2016-FXY-006</org_study_id>
    <nct_id>NCT02961998</nct_id>
  </id_info>
  <brief_title>Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail</brief_title>
  <official_title>Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is a common fatal malignant tumor, although with the&#xD;
      popularity of health examination, most patients were diagnosed as HCC in advanced stages so&#xD;
      far. Sorafenib is currently recognized worldwide as the only effective treatment for advanced&#xD;
      HCC. However, sorafenib need long-term medication, and will bring a series of side effects,&#xD;
      including, hand, foot and comprehensive syndrome (Hand-foot syndrome, HFS) limbs swelling,&#xD;
      rash, peeling, pain.Occurrence rate of HFS is about 21%-51%, which seriously affect patient's&#xD;
      quality of life.Besides, this side effects appeared to be dose-related.When severe HFS&#xD;
      happened, sorafenib need to reduce dosage or discontinue administration, which could&#xD;
      seriously affect the patient's survival. Therefore, investigators designed this prospective&#xD;
      randomized controlled study to explore preventive effect of celecoxib for sorafenib related&#xD;
      HFS, the influence on the quality of life in patients with, and also the synergistic&#xD;
      anti-tumor effect of celecoxib in combination with sorafenib on HCC. This study will explore&#xD;
      horizon of improving treatment for sorafenib in patients with advanced HCC,quality of life&#xD;
      and tumor control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of participants with clinically definite Sorafenib-related Hand Foot Syndrome</measure>
    <time_frame>within the first 6 months after sorafenib administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Celecoxib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients take sorafenib only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Patients from experimental group will take celecoxib, except for sorafenib</description>
    <arm_group_label>Celecoxib group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Each group will receive sorafenib as basic treatment.</description>
    <arm_group_label>Celecoxib group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Diagnosed with HCC according to the Primary liver cancer diagnosis and treatment&#xD;
             practices published by the Ministry of Health in 2011 China&#xD;
&#xD;
          -  2.A Karnofsky Performance Status (KPS) score ≥70 points&#xD;
&#xD;
          -  3.Age between 18 and 70 years&#xD;
&#xD;
          -  4.Child-Pugh classA or B (class B patients had scores no greater than 7 points). In&#xD;
             addition, the baseline laboratory tests had to meet the following criteria: white&#xD;
             blood cells (WBCs) ≥1.5 × 109/L, platelets ≥50 × 109/L, hemoglobin ≥80 g/L, serum&#xD;
             aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2 x the upper limit of&#xD;
             normal (ULN), serum creatinine ≤ 1.5 x ULN, an international normalized ratio&#xD;
             (INR)&lt;1.5 or prothrombin time &lt; the ULN + 4 seconds, albumin ≥30 g/L, and total&#xD;
             bilirubin ≤34mmol/L&#xD;
&#xD;
          -  5.Patients with advanced hepatocellular carcinoma who failed first-line therapy with&#xD;
             surgery，radiofrequency ablation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Pugh Child-Pugh Grade C, or with massive ascites or had a history of hepatic&#xD;
             encephalopathy, or previous history of gastrointestinal bleeding&#xD;
&#xD;
          -  2.Poor general condition or cachexia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minshan Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>September 7, 2019</last_update_submitted>
  <last_update_submitted_qc>September 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongguo Zhou</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>sorafenib</keyword>
  <keyword>celecoxib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

